

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number
WO 03/068267 A1

- (51) International Patent Classification⁷: **A61K 47/44**, 9/02, 9/20
- (21) International Application Number: PCT/SE03/00251
- (22) International Filing Date: 14 February 2003 (14.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0200475-2 15 February 2002 (15.02.2002) SE
- (71) Applicant (for all designated States except US): **LTP LIPID TECHNOLOGIES PROVIDER AB** [SE/SE]; Box 237, S-37424 Karlshamn (SE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **HERSLÖF, Bengt** [SE/SE]; Brunbärsvägen 2, S-11421 Stockholm (SE).
- (74) Agent: **CONIMAR AB**; Box 2086, S-14102 Huddinge (SE).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/068267 A1

(54) Title: COMPOSITION FOR ORAL OR RECTAL ADMINISTRATION

(57) Abstract: A solid pharmaceutical or food supplement tablet or suppository composition has a melting point of 25 °C or higher and comprises a continuous lipid component comprising one or more polar lipids, one or more non-polar lipids, optionally one or several of water and mono- to trivalent alcohol in an amount of up to 15% by weight of the composition, and one or more agents selected from pharmacologically active agent and food supplement agent. Also disclosed is a corresponding tablet and a corresponding suppository, processes for the production of the composition and the tablet and the suppository, and a method of treating conditions amenable to preventive or therapeutic treatment by administration of the tablet or suppository.

COMPOSITION FOR ORAL OR RECTAL ADMINISTRATION

FIELD OF THE INVENTION

5 The present invention relates to a pharmaceutical tablet and suppository composition for oral or rectal administration based on lipid carrier materials and to methods for its manufacture and administration.

10 BACKGROUND OF THE INVENTION

 From a standpoint of patient convenience and production technology the most attractive pharmaceutical form for oral administration of pharmaceutical agents is the
15 tablet but in some cases also rectal administration by a suppository may be advantageous. However far from all pharmaceutical agents are easily formulated as tablets or suppositories. This is true, in particular, to many active principles which are not easily absorbed from the
20 gastrointestinal tract and require, for optimal absorption to be delivered in pharmaceutical carriers comprising lipids which cannot be compounded as tablets or suppositories. Hard or soft shell capsules have to be used instead. However the preferred capsule material gelatin often is not sufficiently
25 inert towards pharmaceutical excipients of this sort and limits the shelf life of the capsule preparation or requires the use of hard gelatin capsules. Hard gelatin capsules are however particularly inconvenient to swallow. In recent years there has also been some concern among consumers in regard of
30 gelatin obtained from animal sources.

 On the other hand oral administration of pharmaceutical agents in lipid based carriers contained in capsules undeniably has resulted in improved drug performance in terms of bioavailability. Examples include such compounds
35 as cyclosporin and saquinavir, marketed under the name of

Sandimmun Neoral®, Novartis and Invirase®, Roche respectively. Such lipid based carriers are either oily liquids, such as microemulsions, or dispersions, such as emulsions or liposomal preparations, which cannot be easily incorporated
5 into tablets.

Numerous reports describe the use of lipids as tablet excipients in combination with non-lipid constituents. A background of the state of the art in regard of tablet formulations is given in "Modern Pharmaceutics" (Editors G.
10 Banker and C. Rhodes, Marcel Dekker Inc., New York 1996, chapter 10, pp 333 - 394). Most tablets are manufactured by means of powder compression. The pharmaceutical agent(s) is (are) mixed with the excipients to produce a free-flowing powder. Among commonly used excipients are several that can
15 be classified as lipids, for example glycerol triacetate, glycerol behenate, glycerol palmitostearate, zink stearate, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils, and waxes. Other lipophilic ingredients include paraffins and light mineral oils. Also
20 synthetic lipophilic and amphiphilic ingredients are used, such as polyethylene glycols (PEG), polyoxyethylene monostearates, sodium lauryl sulphate, and sucrose monolaurate.

Most of the aforementioned lipid ingredients act as
25 soluble or insoluble lubricants. They are combined with other types of ingredients, such as fillers (e.g., lactose and starch), binders (e.g., starch mucilage), and disintegrants (e.g., microcrystalline cellulose and cross-linked polyvinylpyrrolidone). Besides their lubricating function
30 lipid ingredients have been used in controlled release formulations.

WO 95/20945 discloses a lipophilic carrier preparation in form of an oily liquid or dispersion having a continuous lipid phase, comprising a non-polar lipid in combination with a
35 polar lipid material, and optionally a polar solvent, polar

lipid material being a galactolipid material consisting of at least 50 % digalactosyldiacylglycerols, the remainder being other polar lipids.

WO 92/05771 discloses a lipid particle forming matrix
5 containing bioactive material(s) comprising at least two lipid components, one being non-polar and the other amphiphatic and polar. When brought in contact with an aqueous solvent the matrix spontaneously forms discrete lipid particles. The amphiphatic and polar lipid matrix components
10 are said to be bilayer forming and are chosen from phospholipids such as phosphatidylcholine; the non-polar lipids are mono-, di- or triglycerides.

OBJECTS OF THE INVENTION

15

It is an object of the invention to provide a solid pharmaceutical or food supplement tablet or suppository composition which exploits the advantageous properties of lipids as pharmaceutical carriers in regard of gastro-
20 intestinal uptake and/or sustained release and/or convenience and/or economy.

It is another object of the invention to provide a corresponding carrier composition for incorporation of pharmacologically active or food supplement agents.

25

It is a further object of the invention to provide processes for making the aforementioned compositions and for incorporating a pharmacologically active agent or food supplement into said carrier composition.

Further objects of the invention will be evident from
30 the following short description of the invention, the description of preferred embodiments, and the appended claims.

SHORT DESCRIPTION OF THE INVENTION

According to the present invention is disclosed a solid pharmaceutical or food supplement tablet composition which has a melting point of from 25°C to 50°C or more, preferably from 30°C to 45°C, more preferred from 33°C to 42°C, comprising a continuous lipid phase comprising, preferably consisting of, a polar lipid component, a non-polar lipid component, and a pharmacologically active agent.

The polar lipid component consists of one or more polar lipids. The non-polar component consists of one or more non-polar lipids. The one or more polar lipids are membrane lipids, in particular glycolipids and phospholipids. The one or more non-polar lipids are preferably glycerides, i.e. glycerol esters of fatty acids (mono-, di-, and triglycerides). All polar and non-polar lipids of the invention can be sourced from foodstuffs or food grade material. The polar lipids of the invention are amphiphilic with headgroups such as galactose or phosphate esters. The polar lipid component of the invention is combined with the non-polar lipid component in various proportions to allow the controlled incorporation of pharmaceutical including food supplement agents. It is believed that the incorporation mechanism is based on interactions of the polar headgroups and the lipophilic chains of the non-polar component with the compound to be incorporated. Pharmacologically (including food supplementing) efficient compositions for a given pharmacologically active agent or mixture of agents can be experimentally determined by varying the ratio of the polar to non-polar component. To a certain extent the pharmacological or food supplemental efficacy is also influenced by the composition of the polar and non-polar component, respectively.

Preferably the polar component of the composition according to the invention comprises or, more preferred,

consists of one or several polar lipids of vegetable origin, such as oat kernels or soybeans. Preferably the non-polar lipid component of the composition according to the invention comprises or, more preferred, consists of one or several
5 glycerides of vegetable origin, such as palmkernel oil, coconut oil, palm oil and cottonseed oil.

It is particularly preferred for the solid pharmaceutical or food supplement tablet or suppository composition of the invention to comprise lipid material of
10 vegetable origin only.

According to the present invention is also disclosed a solid tablet produced from the aforementioned pharmaceutical or food supplement composition, in particular by compression moulding or casting.

15 According to the present invention is also disclosed a suppository produced from the aforementioned pharmaceutical composition, in particular by compression moulding or casting.

In the pharmaceutical literature lipid continuous
20 phases are described as oily liquids, which need to be administered as oral liquids or enclosed in hard or soft shell capsules. However, such oily liquids are completely outside of the scope of the present invention. Lipid phases are also known in form of dispersions, i.e. dispersed aqueous
25 solvents. Lipid emulsions and liposome preparations are examples of such dispersions which, by definition, are not lipid continuous phases and therefore do not form part of the present invention.

The polar component of the invention can be described
30 as formed of membrane lipid(s), i.e. the lipid constituents of biological membranes. Membrane lipids contain a polar, hydrophilic, head group and one or more lipophilic hydrocarbon chains. This combination makes the membrane lipid molecules amphipathic and enables them to associate both with
35 water and oils. Such membrane lipids can be classified

according to their chemical structure, which is a function of how the polar head group is linked to the lipophilic chains. Sphingolipids (linked by sphingosine) and glycerolipids (linked by glycerol) are the two main groups. Depending on

5 the characteristics of the polar head group sphingolipids and glycerolipids can be further classified as phospholipids, with the head group being a phosphate ester, or as glycolipids, with the head group being a carbohydrate. Depending of the specific nature of the carbohydrate group

10 membrane lipids sometimes are called, for example, galactolipids, which are glycerolipids with galactose in the polar head group. Examples of common membrane lipids are phosphatidylcholine (PC), phosphatidylethanolamine (PE), and digalactosyl-diacylglycerol (DGDG). The membrane lipids can

15 be extracted from, for example, egg yolk (egg lecithin), milk and dairy products, soybeans (soy lecithin), other oil crops, oat kernels, and other cereals and grains. These extracts can be further treated to become, for example, PC from soybeans and galactolipids from oats. Preferred polar lipids are

20 galactolipids, in particular galactolipids from oat kernels (CPL-galactolipid) or from soybeans (soy lecithin or soy-PC). Particularly preferred are partially hydrolysed galactolipids.

Synthetic polar lipids and membrane lipid analogues

25 based on a carbohydrate or phosphate ester moiety are comprised by the polar lipid component of the invention.

The preferred non-polar lipids of the invention are fatty acid esters of glycerol. These esters include mono-, di-, and triglycerides. Edible oils are triglyceride oils,

30 from which mono- and diglycerides can be derived. Other non-polar lipids of the invention include vegetable and animal oils from various sources, synthetic oils, fatty acids, natural and synthetic glycerides, sterol esters, fatty alcohols. Synthetic non-polar lipids and fatty acid analogues

35 are also comprised by the invention. A description of the

area of polar and non-polar lipids is given in "Fatty Acid and Lipid Chemistry" (Frank Gunstone, 1996, Blackie Academic & Professional, Chapman & Hall).

The triglyceride may be selected from palmkernel oil
5 or natural oils with similarly, relatively high solid fat content or melting range. Preferred non-polar lipids include palmkernel oil fractions, obtained by commercial fractionation of palmkernel oil into specific mixtures of triglycerides, e.g. palmkernel stearin, based on the
10 combination of mainly lauric, myristic, and palmitic esters of glycerol. Preferred monoglycerides are selected from edible oil derived monoglycerides, in particular medium chain monoglycerides (chain length $C_8 - C_{10}$), derived from coconut oil, and normal chain monoglycerides (chain length $C_{16} - C_{18}$),
15 derived from most vegetable oils.

According to a preferred aspect of the invention the continuous lipid phase may comprise up to 15% by weight, preferably up to 10% by weight, most preferred up to 5% by weight of water and/or an alcohol, including an alkanediol or
20 -triol, such as ethanol, 1,2-propylene glycol, low molecular weight polyethylene glycol, and glycerol. By definition the continuous lipid phase cannot comprise more water or alcohol than is compatible with its property of being continuous.

According to the invention is also disclosed a
25 pharmaceutical or food supplemental or suppository carrier composition consisting of a continuous lipid phase having a melting point of from 25°C to 50°C or more, preferably from 30°C to 45°C, more preferred from 33°C to 42°C, comprising, preferably essentially consisting of, a polar lipid component
30 in combination with a non-polar lipid component.

According to the present invention is furthermore disclosed a process for the production of a pharmaceutical or food supplement tablet composition or suppository composition which has a melting point of from 25°C to 50°C or more,
35 preferably from 30°C to 45°C, more preferred from 33°C to

42°C, comprising a continuous lipid phase comprising, preferably consisting of, a polar lipid component, a non-polar lipid component and a pharmacologically active chemical agent or food supplementing agent, comprising mixing a polar
5 lipid component with a non-polar lipid component at a first temperature at which at least one of said components is in a liquid state, thereby obtaining a liquid continuous lipid phase, dissolving one or more of said agents in the liquid continuous lipid phase, cooling the solution thus obtained or
10 aliquots thereof to a second temperature at which it solidifies, said second temperature ranging from 25°C to 50°C or more, preferably from 30°C to 45°C, more preferred from 33°C to 42°C. The cooling may produce a cake if carried out in bulk or a powder if the liquid product is fed to a nozzle,
15 preferably at a temperature slightly above its melting point, and sprayed on, for instance, a cooled metal surface, in particular a polished chromium plated stainless steel surface in form of a band running on rollers. A powdery product may also be obtained by spraying the liquid product into a
20 atmosphere of a temperature below the solidification temperature of the liquid product. The cake may be transformed into powder by, for instance, grinding at a low temperature.

According to a second preferred aspect is disclosed a
25 tablet or suppository of the invention coated with one or several layers of tablet or suppository, respectively, coating excipients, such as to provide the tablet or suppository with an enteric coat and/or a coat physically stabilizing the tablet or suppository at a temperature at or
30 above its melting point, and a corresponding coating process. Particularly preferred is a tablet or suppository of the invention provided with a first or only coat applied by a dry coating process comprising mechanically working a coating powder into the surface of the tablet or suppository at a
35 temperature at which the tablet or suppository is

sufficiently soft for the powder particles to adhere and allow them being worked into its surface but not sufficiently soft for substantial deformation, in particular at a temperature from 25°C to 10°C below the melting point of the
5 tablet or suppository. One or more additional layers may be added to the thus coated tablet or suppository by routine pharmaceutical coating processes known in the art. The tablet or suppository of the invention may also be built up around an inert nucleus.

10 A tablet or suppository according to the invention can be produced from the pharmaceutical or food supplement tablet composition of the invention by compressing the aforementioned powdery product or by moulding or any other suitable process. According to a preferred aspect of the
15 invention the moulding is carried out in a mould covered with an anti-adhering agent or layered with an anti-adhering material, such as amorphous silica, cornstarch and sodium lauryl sulphate, and poly(perfluoro-ethylene), respectively.

The pharmaceutical agent or agents of the invention
20 can be of any type suitable for forming a tablet or suppository composition with the pharmaceutical carrier of the invention, with the proviso that the pharmaceutical agent or agents is soluble in the pharmaceutical carrier and is stable at a temperature above 30°C, preferably above 33°C,
25 most preferred above 40°C, for a time sufficient to incorporate it into the pharmaceutical carrier. In this context "stable" means that no more than 5% by weight of the pharmaceutical agent(s), preferably not more than 2% by weight, most preferred not more than 1% by weight, is
30 degraded or lost during the incorporation process. The term "pharmaceutical agent" comprises any substance that prevents, cures or alleviates an aberrant health state, such as a nutritional defect, in particular vitamin deficiency or a deficiency of essential amino acids, and any substance used
35 for diagnostic purposes which is per-orally administrable.

The pharmaceutical agent of the invention can be any of analgesics, anti-inflammatory agents, antihelmintics, anti-antiallergic agents, arrhythmic agents, antibacterial agents, anti-coagulants, antidepressants, antidiabetic agents, anti-
5 epileptics, antifungal agents, antigout agents, anti-histamines, antihypertensive agents, antimalarial agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, antiprotozoal agents, antithyroid agents, antiviral agents, anxiolytic agents, betaadrenoceptor
10 blocking agents, cardiac inotropic agents, corticosteroids, cough suppressants, diagnostic agents, diuretics, dopaminergics, enzymes, gastro-intestinal agents, hypnotics, hypothalamic hormones, immunological agents, immunosuppressants, lipid regulating agents, mucolytics, muscle relaxants, neuro-
15 leptics, nutritional agents, opoid analgesics, parasympathomimetics, pituitary hormones, parathyroid agents, prostaglandins, sedatives, sex hormones, sympathomimetics, thyroid agents, vasodilators, vitamins, and xanthines. The requirements for incorporation of food supplement agents in
20 the tablet of the invention correspond to those of pharmacologically active agents.

By way of examples it was surprisingly found that the solid pharmaceutical or food supplement tablet or suppository composition of the invention not only can incorporate a wide
25 variety of pharmacologically active agents or food supplement agents of vastly differing chemical structures, but also increases its uptake in the gastrointestinal tract and/or prolongs its efficacy. The present invention thus provides a novel way of improving and widening the use of tablet
30 compositions for pharmaceutical use including food supplement use.

In the following the invention will be explained in more detail by the following, non-limiting examples.

DESCRIPTION OF PREFERRED EMBODIMENTS

Materials. The lipid materials used are listed in Table 1.

- 5 If not indicated otherwise all percentages in the description of preferred embodiments are by weight.

Table 1. Lipid materials

Type of lipid	Trade name and source
PL-1	Galactolipids from oats (CPL-Galactolipid; Lipid Technologies Provider AB, Karlshamn, Sweden)
PL-2	PC from soybeans (prepared from soy lecithin Epikuron 135 F; Lucas Meyer GmbH&Co, Hamburg, Germany)
MG-1	Medium chain monoglyceride (Akoline MCM; Karlshamns AB, Karlshamn Sweden)
MG-2	Monoglycerides from edible oils (Dimodan CP; Danisco, Copenhagen, Denmark)
TG-1	Palmkernel stearin (fraction of palmkernel oil ; Karlshamns AB, Karlshamn Sweden)
TG-2	Hydrogenated cotton seed oil (Akofine NF; Karlshamns AB, Karlshamn Sweden)

10

EXAMPLE 1. Exemplary preparation of a tablet by compression of a powdery mixture of lipids (Method A).

A mixture of the following ingredients (in g) was prepared:

15

Non-polar lipids (hydrogenated triglycerides; Akofine™)	18,00
Polar lipid material (galactolipids; CPL-Galactolipid™)	2,00
Vitamin B12	0,040

20

The powdery ingredients were blended in a dry mixer. Aliquots (0.50 g) of the homogenous powder were compressed to tablets in a manually operated press (Manesty Machines Ltd, Model no D3). It is also possible to prepare a suppository in this manner by using an appropriate press-form.

25

EXAMPLE 2. Exemplary preparation of a tablet by casting molten lipid mixture into a mould (Method B).

Ingredients (in g):

5	Non-polar lipids (fractionated triglycerides; palmkernel stearin)	18,00
	Polar lipid material (galactolipids; CPL-Galactolipid™)	2,00
	Vitamin B12	0,040

- 10 The ingredients were blended and the mixture melted by heating to a temperature of 60°C and stirred at this temperature for 5 hours when all vitamin B12 had dissolved. Aliquots (0.50 g) of the melted phase were cast in a mould covered with hydrogenated triglyceride (Akofine NF™) powder.
- 15 The mould was cooled in a freezer and the tablets recovered. A suppository can be prepared in a corresponding manner by using an appropriate mould.

EXAMPLE 3. Preparation of tablets containing vitamin B12, folic acid, retinyl palmitate or desmopressin (as acetate).

Tablets were prepared according to Method A (as described in Example 1) or Method B (as described in Example 2) with several carrier compositions (Table 1) according to the invention. The 17 preparations thus produced and their relative efficacies are listed in Table 2.

The results demonstrate that the proportions and structure of the lipid phase components affect bioavailability. A range from highly improved (by a factor of 5.3) uptake to highly suppressed uptake, i.e. virtually nil, was observed.

Table 2. Pharmaceutical/food supplement tablet preparations

Prep. no.	Method	Active principle/tablet (0.5 g)	Lipids (% by weight)			Efficacy (Reference = 100)
		Vitamin B12 (mg)	Polar (% by weight)	Non-polar lipid (% by weight)		
				Glyceride I	Glyceride II	
1	B	1	20 (PL-1)	5 (MG-1)	75 (TG-1)	33
2	B	1	20 (PL-1)	10 (MG-1)	70 (TG-1)	74
3	B	1	20 (PL-1)	15 (MG-1)	65 (TG-1)	529
4	B	1	20 (PL-1)	20 (MG-1)	60 (TG-1)	191
5	B	1	20 (PL-1)	30 (MG-1)	50 (TG-1)	100
6	B	1	45 (PL-1)	35 (MG-1)	20 (TG-1)	355
7	B	1	57 (PL-1)	43 (MG-1)	0	148
8	B	1	10 (PL-1)	0	90 (TG-1)	108
9	A	1	10 (PL-1)	0	90 (TG-2)	6
10	B	1	20 (PL-1)	15 (MG-2)	65 (TG-1)	43
11	B	1	20 (PL-2)	15 (MG-1)	65 (TG-1)	71
12	B	1	20 (PL-2)	20 (MG-1)	60 (TG-1)	0
		Folic acid (mg)				
13	B	5	20 (PL-1)	10 (MG-1)	70 (TG-1)	93
14	B	5	20 (PL-1)	15 (MG-1)	65 (TG-1)	117
15	B	5	20 (PL-1)	20 (MG-1)	60 (TG-1)	56
16	B	5	10 (PL-1)	0	90 (TG-1)	81
17	A	5	10 (PL-1)	0	90 (TG-2)	1
		Retinyl palmitate (mg)				
18	B	33 (50000 IE)	10 (PL-1)	0	90 (TG-1)	115
19	A	33 (50000 IE)	10 (PL-1)	0	90 (TG-2)	6
		Desmopressin* (µg)				
20	B	50	20 (PL-1)	15 (MG-1)	65 (TG-1)	**

* As acetate. ** See Example 5

EXAMPLE 4. Test of tablet preparations in healthy human

5 volunteers. Tablet preparations of vitamin B12, folic acid, and retinyl palmitate respectively were tested in healthy human volunteers. As reference each person was also given the same dose of active principle in form of a commercial tablet preparation (vitamin B12: Behepan®, Pharmacia; folic acid,

10 Folacin®, Pharmacia; retinyl palmitate: Arovit®, Roche). The observed differences in blood concentration over a given period of time are expressed as percentage of the reference, which was set at 100. Thus a result above 100 for the compositions of the invention indicates an increased plasma

15 concentration of the active principle and thus an increased

pharmacological efficacy. These tests were performed with an interval of one week.

The subjects were fasting (intake of water allowed) since 10 p.m. the day before testing. On the testing day the
 5 persons arrived at the clinic at 07.00 a.m.. An intravenous catheter was installed in an arm vein for sampling of blood. The tablet was taken at about 7.30 a.m.. A series of blood samples were drawn as outlined in Table 3. In addition

10 *Table 3. Plasma sampling pattern for vitamin B12, folic acid, and retinyl palmitate*

<i>Hours after dosing</i>	<i>0,5</i>	<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>6</i>	<i>8</i>
<i>Compound</i>							
Vitamin B12		x	x	x	x	x	x
Folic acid	x	x	x	x	x	x	x
Retinyl palmitate		x	x	x	x	x	x

a pre-dosing sample was taken. A standardised lunch was served after the sampling at 4 hours after administration.

15 The blood samples were treated and analysed in accordance with GCP and validated analytical methods provided by the Laboratory of Clinical Chemistry; Lund University Hospital, Lund, Sweden, and the Laboratory of Clinical Chemistry, Huddinge Hospital, Sweden. Plasma concentrations
 20 were plotted against time. The area under the curve obtained from the reference tablet was defined as 100, and the area under the curve (AUC) from the corresponding tablet of the invention was expressed as a percentage of the reference.

The AUC was calculated by the linear trapezoidal rule
 25 to the last blood concentration. Except for preparations no. 13, 14, 15 the concentration of the samples taken before administration was regarded as baseline and subtracted from the concentration of sample taken after administration since no samples prior to administration were taken in the latter
 30 preparations; the plasma conc. of active principle at start was set to zero. The results are given in Tables 2 and 4-6.

Indicates the preparation number (see Table 2).

Table 4. Serum concentration pmol/L of vitamin B12

Time (h)	Ref.	#1	#3	#10	Ref.	#2	#5
0	310	379	300	305	274	258	281
1	409	358	1130	323	373	319	387
2	388	375	861	337	376	290	363
3	420	404	893	346	385	353	369
4	421	400	807	352	392	354	397
6	413	457	787	361	375	330	384
8	431	452	710	370	357	355	397
% Ref.		33	529	43		74	100

Ref.	#4	#7	Ref.	#6	Ref. *	#8*	#9*
183	177	169	233	218	279	319	293
239	426	376	262	574	361	382	301
295	375	316	303	473	445	475	290
293	367	341	317	444	446	496	297
311	380	302	317	432	437	495	298
285	366	313	311	412	431	521	309
288	343	311	254	397	443	465	315
%Ref.	191	148		355		108	6

5

Ref.	#11	Ref.	#12
233	236	271	306
354	309	286	284
330	350	322	274
316	310	313	280
316	314	324	252
313	241	329	348
323	330	337	301
%Ref.	71		0

Table 5. Serum concentration (nmol/L) of folic acid

Time (h)	Ref.	#13	#15	Ref.	#14
0,5	25	132	48	9	113
1	50	399	193	10	193
2	147	504	204	162	208
4	525	231	170	273	252
8	120	63	95	86	97
% Ref.		93	56		117

Time (h)+A55	Ref.	#16	#17
0	14,8	25	23,7
0,5	24,8	96	21,7
1	301	429	20,7
2	679	477	26,2
3	453	337	27,2
4	338	318	29,8
6	216	152	27,6
8	117	100	26
% Ref.		81	1

Table 6. Serum concentration (micromol/L) of retinyl palmitate

5

Time (h)	Ref.	#18	#19
0	0,02	0,04	0,03
1	0,03	0,07	0,03
2	0,04	0,48	0,04
3	0,38	1,19	0,05
4	0,79	0,92	0,05
6	1,83	1,52	0,13
8	0,53	0,64	0,12
% Ref.		115	6

EXAMPLE 5. Test of tablet preparations with desmopressin (anti-diuretic) in healthy human volunteers. This tablet preparation was tested by means of measuring the amount of urine produced over a given period of time according to procedures described in the literature (Hans Vilhardt and Stefan Lundin, *Gen. Pharmac.* 17 (1986) 481-483). The healthy male volunteers were fasting since 10.00 p.m. the day preceding the test. On the following morning the subject drank an amount of tap water corresponding to 1.5 % of his body weight. Then the urine was collected every 15 minutes. The collected volume was measured and an equal volume of tap water was ingested immediately thereafter. The tablet was taken when the collected volume of urine per period of 15 min exceeded 150 ml. A light breakfast was given one hour after administration of desmopressin, and a light lunch 3 hours later. The liquids consumed to these meals were included in the ingested volumes replacing the collected urine.

The result of the test is expressed as percentage of the accumulated urine production in the tablet of this invention compared to half of the commercial reference tablet containing 100 µg of desmopressin (Minirin®, Ferring) over a period of 11 hours starting 30 min after administration.

The desmopressin composition according to the invention (Preparation 17) increased the anti-diuretic effect of desmopressin 3.5 times in terms of volume of urine produced over a period of 11.5 hours after administration (see, Tables 2 and 7).

EXAMPLE 6. Preparation of a carbohydrate coated continuous lipid phase tablet. Vitamin B12 tablets (EXAMPLE 2; 60 g) were fed to a coating cylinder. Simultaneously a powdery mixture of 68% acacia gum, 20% lactose and 12% dextrose (3% by weight of the tablets) was introduced into the cylinder. The mixture was rotated at 30 rpm for 3 hrs at 18°C. The tablets with a smooth surface obtained can be further coated by traditional pharmaceutical coating methods, such as by fluidised bed coating (see, for instance: S C Porter and C H Bruno, *Coating of Pharmaceutical Solid-Dosage Forms*, in: *Pharmaceutical Dosage Forms*, H A Lieberman et al., Eds., 2nd Ed. Vol. 3, p. 77-160, Marcel Dekker, New York and Basel 1990, and literature cited therein).

25

30

35

Table 7. Urine collected after administration of desmopressin

Min after administration	Collected urine (ml)	
	Preparation 17	Reference.
30	0	42
45	0	0
60	0	0
75	0	24
90	0	0
105	0	0
120	0	0
150	0	0
180	0	50
210	0	42
240	140	48
270	46	60
300	34	66
330	32	84
360	30	120
390	18	120
420	20	158
450	44	206
480	70	208
510	40	216
555	28	322
600	42	438
645	98	448
690	236	432
Accumulated volume	878	3084

EXAMPLE 7. Preparation of a continuous lipid phase tablet

5 containing 1.8 mg of porcine insulin (Method B). Materials,
by weight:

- Non-polar lipids (medium chain monoglycerides; MCMG)
180 parts;
- Non-polar lipids (fractionated triglycerides;
10 palmkernel stearin), 450 parts;
- Polar lipid material (galactolipids; CPL-
Galactolipid™), 240 parts;
- Insulin, 1.8 parts;
- 4% Aqueous sodium bicarbonate, 28.2 parts.

Porcine insulin (Sigma, no. I 5523) was dissolved in the sodium bicarbonate solution at 60°C. The monoglyceride was added and the mixture was stirred until a clear liquid had formed. The galactolipids and the palmkernel stearin were subsequently added stepwise at the same temperature. Stirring was continued until clear liquids had formed. On cooling the liquid corresponding to the tablet composition solidified; m.p. 33°C. Aliquots (500 mg) of the molten composition were cast in a mould covered with hydrogenated triglyceride (Akofine NF™) powder. The mould was cooled in a freezer. Upon solidification the solid tablets were recovered by hand.

EXAMPLE 8. Useful commercially available synthetic lipid materials (examples): Mono- and diglyceride acetates; mono- and diglyceride citrates; mono- and diglyceride lactates; polyglycerol esters of fatty acids; propyleneglycol esters of fatty acids; sorbitane esters of fatty acids; Sodium and calcium stearyl lactates; diacetyl tartaric acid esters of mono- and diglycerides; diglycerol esters of fatty acids.

EXAMPLE 9. Useful commercially available food supplement and other supplementary materials for incorporation into a tablet of the invention (examples): Amino acids, vitamins and other food supplement agents, in particular lecithin, linseed oil, melatonin, mono-octanoin, peptides, in particular di- to decapeptides, biotin, carnitine, cystine, methionine, isoleucine, leucine, ornithine, lysine acetate, folic acid, vitamin D, cholecalciferol, Vitamin E.

EXAMPLE 10. Gentamycin sulphate compositions. The following gentamycin sulphate compositions of the invention ("Gentamycin 2", "Gentamycin 3", "Gentamycin 4") were prepared (Table 8).

Table 8. Gentamycin sulphate compositions

Batch #	Gentamycin sulphate	Composition
W 21212-N1 "Gentamycin 1"	Gentamycin sulphate batch no. 070K1038; Experimental batch size: 120 mg	Gentamycin sulphate 100%
W 20920-N3 "Gentamycin 2"	Gentamycin sulphate batch no. 070K1038; Experimental batch size: 2×4.75g	Gentamycin sulphate 50mg = 1.05%; H ₂ O 0.5g = 10.5%; Lyso-PC 0.5g = 10.5%; CPL-GL 1.05g = 22.1%; MCMG 1.15g = 24.2%; PK stearin 1.5g = 31.6%
W 20920-N2 "Gentamycin 3"	Gentamycin sulphate batch no. 070K1038; Experimental batch size: 2×4.75g	Gentamycin sulphate 50mg = 1.05%; H ₂ O 0.5g = 10.5%; CPL-GL 1.55g = 32.6%; MCMG 1.15g = 24.2%; P stearin 1.5g = 31.6%
W 21106-N2 "Gentamycin 4"	Gentamycin sulphate batch no. 070K1038; Experimental batch size: 4.0g	Gentamycin sulphate 120mg = 3%; H ₂ O 0.4g = 10%; HGL 1.24g = 31%; MCMG 0.92g = 23%; PK stearin 1.32g = 33%

Abbreviations in Table 8: Lyso-PC: lysophosphatidylcholine; HGL: partially hydrolysed galactolipid (Example 12); MCMG: medium chain monoacylglycerol; CPL-GL: CPL galactolipid; PK stearin: palm kernel oil stearin; P stearin: palm oil stearin.

EXAMPLE 11. Vancomycin hydrochloride compositions. The following vancomycin hydrochloride compositions of the invention (Table 9) were prepared by pouring aliquots of the liquid compositions at 50°C into hard gelatin capsules and allowing them to cool and solidify in place.

Table 9. Vancomycin hydrochloride compositions

Batch #	Batch size (g)	Composition	Observations
W 21029-N1 "Vancomycin 1"	1.0	Vancomycin hydrochloride: 20mg = 2%; H ₂ O: 0.15g = 15%; HGL: 0.16g = 16%; CPL-GL: 0.14g = 14%; MCMG: 0.22g = 22%; PK stearin: 0.31g = 31%	
W 21107-N1 "Vancomycin 2"	1.0	Vancomycin hydrochloride: 20mg = 2%; H ₂ O: 0.15g = 15%; CPL-GL: 0.31g = 31%; MCMG: 0.23g = 23%; cholesterol 0.1g = 10%; PK stearin: 0.19g = 19%	Substantial improvement over "Vancomycin 1"
W 21209-N3 "Vancomycin 3"	6.0	Vancomycin hydrochloride: 120mg = 2%; H ₂ O: 0.9g = 15%; CPL-GL: 1.86g = 31%; MCMG: 1.38g = 23%; cholesterol 0.6g = 10%; PK stearin: 1.14g = 19%	Ca. 85% of water can be removed by evaporation at 60°C; improvement over "Vancomycin 2"

For abbreviations, see Table 8

EXAMPLE 12. Preparation of partially hydrolysed galactolipid (HGL). Galactolipid (40 g) was dissolved in MeOH (2.0 L) assisted by ultrasound. Aqueous NH_3 (25%; 10 ml) was added. The mixture was shaken at room temperature for 23 hrs; a
5 yellowish green colour and a small amount of a lightly coloured precipitate had formed. The solution was evaporated on a rotary evaporator under reduced pressure. 400 ml of acetone was added to extract free fatty acids. After repeated evaporation at 60°C and standing over night the supernatant
10 was decanted and the residue evaporated and freeze dried after addition of water (300 ml). 31.7 g of a gel containing about 12% of DGMG (digalactosyl-monoacylglycerol), less than 1% of fatty acid methyl esters, and about 2% of digalactosyl-glycerol was formed. The content of DGDG (digalactosyl-
15 diacylglycerol) thus had been reduced to about 40%.

EXAMPLE 13. Administration of gentamycin. NZW rabbits were used in all experiments and all tablet/capsules were administered orally. The animals were given four, five or six
20 tablets/capsules followed by water until they had swallowed the tablets/capsules. The animals were deprived of food for about 18 hours before dosing. Blood samples were drawn from the ear veins in sodium citrate vials before dosing and 0.5, 1, 2, 6 and, in some cases, 3 hours after dosing. The blood
25 samples were centrifuged for 10 min at approximately 2000×g to obtain plasma for determination of gentamycin by EMIT 2000 TDM assay on a Hitachi 704 Analyzer (Table 10).

The area under the curve (AUC) was calculated by the linear trapezoidal rule to the last blood concentration. Two
30 different doses (5 or 10 mg/kg bodyweight) were used during the experiments. For comparison of the results of the different formulations the AUC was divided by the respective dose of gentamycin. The obtained plasma concentration for pure gentamycin was set to 1. The obtained plasma
35 concentrations for gentamycin in the three different lipid

formulations were then expressed as multiple factors of increasing bioabsorption. Thus, Gentamycin 2 gave 12 times higher absorption than Gentamycin 1 due to incorporation of gentamycin in the lipid matrix.

Table 10. Plasma concentration of gentamycin (microgram/mL) after oral administration to rabbits

Time after administration (hrs)	Gentamycin 1 (in substance) Dose 10 mg/kg; n=3	Gentamycin 2 (in lipid matrix); dose 5 mg/kg; n=4	Gentamycin 3 (in lipid matrix); dose 5 mg/kg; n=4	Gentamycin 4 (in lipid matrix); dose 10 mg/kg; n=3
0	0	0	0	0
0.5	0.01	0.07	0.09	0.10
1	0.01	0.22	0.04	0.07
2	0.02	0.11	0.07	0.08
3	-	0.06	0.06	-
4	0.01	0.06	0.05	0.09
6	0.03	0.09	0.06	0.08
AUC	0.09	0.55	0.34	0.48
AUC adjusted to mg/kg given dose	0.009	0.11	0.068	0.048
Correlation factor	1	12	8	5

Claims

1. A solid pharmaceutical or food supplement tablet composition which has a melting point of 25°C or higher, comprising a continuous lipid component comprising one or more polar lipids, one or more non-polar lipids, optionally one or several of water and mono- to trivalent alcohol in an amount of up to 15% by weight of the composition, and one or more agents selected from pharmacologically active agent and food supplement agent.
2. The composition of claim 1, substantially consisting of one or more polar lipids, one or more non-polar lipids, and one or more pharmacologically active and/or food supplement agents.
3. The composition of claim 1, substantially consisting of one or more polar lipids, one or more non-polar lipids, water up to 15% by weight, and one or more pharmacologically active or food supplement agents.
4. The composition of claim any of claims 1-3, wherein said one or more polar lipids are membrane lipids.
5. The composition of claim 4, wherein said one or more polar lipids are selected from glycolipids and phospholipids.
6. The composition of claim 5, wherein said one or more polar lipids are selected from glycolipids.
7. The composition of claim 6, wherein said one or more glycolipids are galactolipid(s).
8. The composition of claim 7, wherein at least one of said galactolipid(s) are partially hydrolysed galactolipid(s).
9. The composition of any of claims 1-8, wherein said one or more non-polar lipids are glyceride esters of fatty acids.

10. The composition of any of claims 1-9, wherein said one or more non-polar lipids are lipids of vegetable origin.
11. The composition of claim 10, wherein said one or more
5 non-polar lipids include triglycerides selected from palmkernel oil fractions obtained by commercial fractionation of palmkernel oil.
12. The composition of claim 10, wherein said one or more non-polar lipids include $C_8 - C_{10}$ monoglycerides and/or
10 $C_{16} - C_{18}$ monoglycerides.
13. The composition of any of claims 1 and 3-12, comprising water and/or one or more of mono- to trivalent alcohol.
14. The composition of claim 13, wherein the monovalent
15 alcohol is ethanol.
15. The composition of claim 13, wherein the divalent to trivalent alcohol is selected from 1,2-propylene glycol, low molecular weight polyethylene glycol, glycerol.
- 20 16. The composition of any of claims 1-15, wherein said pharmacologically active agent is selected from analgesics, anti-inflammatory agents, antihelmintics, antiallergic agents, arrhythmic agents, antibacterial agents, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antifungal agents, antigout
25 agents, antihistamines, antihypertensive agents, antimalarial agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, antiprotozoal agents, antithyroid agents, antiviral agents, anxiolytic agents, beta-adrenoceptor blocking
30 agents, cardiac inotropic agents, corticosteroids, cough suppressants, diagnostic agents, diuretics, dopaminergics, enzymes, gastro-intestinal agents, hypnotics, hypothalamic hormones, immunological agents, immunosuppressants, lipid regulating agents, mucolytics,
35

- muscle relaxants, neuroleptics, nutritional agents, opioid analgesics, parasympathomimetics, pituitary hormones, parathyroid agents, prostaglandins, sedatives, sex hormones, sympathomimetics, thyroid agents, vasodilators, vitamins, and xanthines.
- 5
17. The composition of any of claims 1 and 3-16, comprising up to 10% by weight of water.
18. The composition of claim 17, comprising up to 5% by weight of water.
- 10
19. A process for the production of a pharmaceutical or food supplement tablet composition which has a melting point of from 25°C and higher, comprising:
- mixing one or several polar lipids with one or several non-polar lipids at a first temperature at which at least one of said components is in a liquid state,
 - 15
 - dissolving, in the liquid continuous lipid phase obtained, one or more pharmacologically active agents,
 - 20
 - cooling the solution of said one or more pharmacologically active agents or food supplement agents or portions thereof in the lipid phase to a second temperature at which it solidifies,
 - 25
 - forming tablets by carrying out the cooling step with aliquots of the solution or from a bulk product obtained in the cooling step or
 - forming filled capsules, preferably hard gelatin capsules, by carrying out the cooling step with aliquots of the solution that had been poured into said capsules.
 - 30
20. The process of claim 19, wherein said first temperature is 25°C and higher.
21. The process of claim 19 or 20, wherein said solution is cooled in bulk, comprising forming a powderous product from said bulk product.
- 35

22. The process of claim 19 or 20, wherein said solution is fed to a nozzle and sprayed on a surface or into a cavity having a temperature below the melting point of the liquid, thereby forming a powdery product.
- 5 23. A process for the production of a pharmaceutical or food supplement tablet comprising compressing the powdery product of claim 21 or 22 into a tablet or a suppository.
- 10 24. The process of claim 23, comprising covering the punch(es) and/or the die for pressing the tablet or suppository with an anti-adherent prior to compression.
25. The process of claim 24, wherein the anti-adherent is selected from stearic acid or a salt thereof.
- 15 26. The process of claim 19, wherein the cooling is carried out by pouring an aliquot of said solution into a mould, thereby forming a tablet or suppository.
27. The process of claim 26, wherein the mould is covered with an anti-adherent prior to pouring.
- 20 28. The process of any of claims 23-27, comprising coating said tablet or suppository with one or several powdery pharmaceutical or food supplement excipients.
29. The process of claim 28, wherein said one or several excipients are mechanically worked into the surface of the tablet so as to form a coating.
- 25 30. A pharmaceutical or food supplement tablet or suppository essentially consisting of a continuous lipid phase, optionally comprising an inert nucleus, wherein the lipid phase may optionally comprise one or several of water and mono- to trivalent alcohol in an amount of up to 15% by weight of the lipid phase, the composition having a melting point of 25°C or higher and comprising one or more polar lipid components in combination with one or more non-polar lipid components, and at least one pharmacologically active agent.
- 30
- 35

31. A pharmaceutical or food supplement tablet or suppository comprising a core which has a melting point of 25°C or higher, the core consisting of a continuous lipid phase and optionally comprising an inert nucleus, the continuous lipid phase comprising one or several polar lipid components, one or several non-polar lipid components, wherein the lipid phase may optionally comprise one or several of water and mono- to trivalent alcohol in an amount of up to 15% by weight of the lipid phase, and one or more pharmacologically active chemical agents, further comprising a coat consisting of pharmaceutical or food supplement excipients.
32. The tablet or suppository of claim 30 or 31, wherein the coat comprises one or more subcoats consisting of pharmaceutical or food supplement excipients.
33. The tablet or suppository of any of claims 30 to 32, wherein the one or more pharmacologically active agent is selected from analgesics, anti-inflammatory agents, antihelmintics, antiantiallergic agents, arrhythmic agents, antibacterial agents, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antifungal agents, antigout agents, antihistamines, antihypertensive agents, antimalarial agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, antiprotozoal agents, antithyroid agents, antiviral agents, anxiolytic agents, beta-adrenoceptor blocking agents, cardiac inotropic agents, corticosteroids, cough suppressants, diagnostic agents, diuretics, dopaminergics, enzymes, gastro-intestinal agents, hypnotics, hypothalamic hormones, immunological agents, immunosuppressants, lipid regulating agents, mucolytics, muscle relaxants, neuroleptics, nutritional agents, opioid analgesics, parasympathomimetics, pituitary hormones, parathyroid agents, prostaglandins, sedatives, sex hormones,

sympathomimetics, thyroid agents, vasodilators, vitamins, and xanthines.

34. The tablet of claim 30-32, wherein the one or more food supplement agents are selected from amino acids and vitamins.
- 5
35. A method of treating or preventing a condition amenable to treatment or prevention by administration of a pharmacologically effective dose of an agent according to of claim 33, characterized in that said agent is administered in form of the tablet or
- 10
- suppository of claim 30-32.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00251

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 47/44, A61K 9/02, A61K 9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI DATA, EPO-INTERNAL, EMBASE, CA DATA, PAJ, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIOSIS, accession no. PREV198784101370, NISHIHATA T et al: "An effective formulation for an insulin suppository examination in normal dogs", International Journal of Pharmaceutics (Amsterdam), 1987, Vol. 38, no. 1-3, pages 83-90, abstract --	30-35
X	BIOSIS, accession no. PREV198681055696, NISHIHATA T et al: "Sustained-release of sodium diclofenac from suppository", International Journal of Pharmaceutics (Amsterdam), 1985, Vol. 27, no. 2-3, pages 245-254, abstract --	30-35
X	DE 2951142 A1 (A. NATTERMANN & CIE GMBH), 9 July 1981 (09.07.81), claims 1-5, page 4, line 25 - page 5, line 4, and the examples --	19-35

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

14 May 2003

Date of mailing of the international search report

19-05-2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Ingrid Eklund/Eö

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00251

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4699776 A (TOSHIKI NISHIHATA ET AL), 13 October 1987 (13.10.87), examples 1-3, the abstract --	19-35
X	US 5989583 A (SHIMON AMSELEM), 23 November 1999 (23.11.99), abstract, column 6, lines 6-31, examples 1-4, claims 1-6 --	1-18, 30-35
X	EP 0368247 A2 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 16 May 1990 (16.05.90), example 2	19-29
Y	--	1-31
X	US 5082667 A (KURT G. VAN SCOIK), 21 January 1992 (21.01.92), abstract, claims 1-3 and 8, examples 1-2	1-35
Y	--	1-35
Y	US 5716639 A (ANDERS CARLSSON ET AL), 10 February 1998 (10.02.98), abstract, column 3, lines 1-7, column 4, lines 1-7 and column 4, line 66 - column 5, line 12 --	1-35
P,X	US 2002040058 A1 (AMANDA JOHANNE KILIAAN ET AL), 4 April 2002 (04.04.02) --	1-35
P,X	WO 0247663 A1 (F. HOFFMAN-LA ROCHE AG), 20 June 2002 (20.06.02) -- -----	1-35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/00251

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **35**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet*
2. ☒ Claims Nos.: **1-4, 5-34 partly**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet**
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/00251

*

Claim 35 relates to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body/Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compound/composition.

**

Present claims 1-4, and partly claims 5-34, relate to an extremely large number of possible compounds. In fact, the claims contain so many options that a lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Expressions such as glycolipids, phospholipids and glyceride esters of fatty acids are not sufficiently specific to be searched completely.

Consequently, the search has been carried out for those parts of the application which appear to be clear and concise, namely the parts that are in accordance with the polar and non polar lipids that are specified in the examples (see table 1).

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00251

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
DE	2951142	A1	09/07/81	NONE		
US	4699776	A	13/10/87	AU	581597 B	23/02/89
				AU	5928486 A	08/01/87
				EP	0210759 A	04/02/87
				JP	62004224 A	10/01/87
US	5989583	A	23/11/99	AU	722217 B	27/07/00
				AU	2433997 A	22/10/97
				BR	9708423 A	04/01/00
				CA	2251194 A	09/10/97
				EP	0954284 A	10/11/99
				IL	117773 A	31/10/00
				IL	126384 D	00/00/00
				JP	2000507594 T	20/06/00
				WO	9736577 A	09/10/97
EP	0368247	A2	16/05/90	SE	0368247 T3	
				AT	106239 T	15/06/94
				AU	645003 B	06/01/94
				AU	3856193 A	26/08/93
				AU	4443789 A	21/06/90
				CA	2002363 A	08/05/90
				DE	68915695 D,T	15/09/94
				DK	555389 A	09/05/90
				HU	211615 B	28/12/95
				HU	9500640 A	28/11/95
				KR	148002 B	17/08/98
				NZ	231281 A	29/01/91
				US	5399357 A	21/03/95
				US	5593690 A	14/01/97
				JP	2223533 A	05/09/90
				JP	2893191 B	17/05/99
				ZA	8908470 A	25/07/90
US	5082667	A	21/01/92	CA	1335257 A	18/04/95
				DE	68906461 D,T	21/10/93
				EP	0345628 A,B	13/12/89
				SE	0345628 T3	
				ES	2057021 T	16/10/94
				JP	2032014 A	01/02/90
				JP	2940937 B	25/08/99

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00251

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5716639 A	10/02/98	AT 199060 T	15/02/01
		AT 201980 T	15/06/01
		AT 201981 T	15/06/01
		AT 224704 T	15/10/02
		AU 678830 B	12/06/97
		AU 691248 B	14/05/98
		AU 691249 B	14/05/98
		AU 691250 B	14/05/98
		AU 1723395 A	21/08/95
		AU 1723495 A	21/08/95
		AU 1723595 A	21/08/95
		AU 6693894 A	21/11/94
		BR 9406363 A	27/02/96
		BR 9506681 A	18/11/97
		CA 2182575 A	10/08/95
		CA 2182576 A,C	10/08/95
		CA 2182577 A,C	10/08/95
		CN 1083713 B	01/05/02
		CN 1091591 B	02/10/02
		CN 1098681 B	15/01/03
		CN 1140405 A	15/01/97
		CN 1140406 A	15/01/97
		CN 1144478 A	05/03/97
		CZ 285795 B	17/11/99
		CZ 9602215 A	13/11/96
		DE 797432 T	19/02/98
		DE 69426669 D,T	05/07/01
		DE 69521300 D,T	02/05/02
		DE 69521338 D,T	28/02/02
		DE 69528355 D	00/00/00
		DK 696921 T	19/03/01
		DK 743851 T	03/09/01
		DK 744939 T	03/02/03
		DK 797432 T	03/09/01
		EE 3220 B	15/10/99
		EP 0696921 A,B	21/02/96
		SE 0696921 T3	
		EP 0743851 A,B	27/11/96
		SE 0743851 T3	
		EP 0744939 A,B	04/12/96
		SE 0744939 T3	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00251

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		EP 0797432 A,B	01/10/97
		SE 0797432 T3	
		ES 2107397 T	01/12/97
		ES 2158084 T	01/09/01
		FI 955124 A	27/10/95
		FI 963064 A	30/09/96
		FI 963065 A	30/09/96
		FI 963066 A	30/09/96
		GR 3035831 T	31/08/01
		GR 97300049 T	30/01/98
		HU 75459 A	28/05/97
		HU 75464 A	28/05/97
		HU 75470 A	28/05/97
		HU 221432 B	28/10/02
		HU 221477 B	28/10/02
		HU 9602141 D	00/00/00
		HU 9602142 D	00/00/00
		HU 9602146 D	00/00/00
		JP 3117145 B	11/12/00
		JP 3203358 B	27/08/01
		JP 3203359 B	27/08/01
		JP 8509493 T	08/10/96
		JP 9508413 T	26/08/97
		JP 9508414 T	26/08/97
		JP 9508415 T	26/08/97
		KR 220546 B	15/09/99
		LV 11726 A,B	20/04/97
		NO 312435 B	13/05/02
		NO 312493 B	21/05/02
		NO 312494 B	21/05/02
		NO 312495 B	21/05/02
		NO 954240 A	23/10/95
		NO 963240 A	02/08/96
		NO 963241 A	02/08/96
		NO 963242 A	02/08/96
		NZ 279952 A	26/02/98
		NZ 279953 A	26/02/98
		NZ 279954 A	26/02/98
		PL 176755 B	30/07/99
		PL 178394 B	28/04/00
		PL 178397 B	28/04/00
		PL 178438 B	28/04/00
		PL 311276 A	05/02/96
		PL 315778 A	09/12/96
		PL 315779 A	09/12/96
		PL 315780 A	09/12/96
		RU 2131267 C	10/06/99
		SE 9400368 D	00/00/00
		SK 135495 A	05/03/97
		SK 280465 B	14/02/00
		TW 402502 B	00/00/00
		TW 482685 B	00/00/00
		US 5688528 A	18/11/97
		US 6022561 A	08/02/00
		WO 9520943 A	10/08/95

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00251

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	5716639	A	10/02/98	WO	9520944 A	10/08/95
				WO	9520945 A	10/08/95
				ZA	9500939 A	09/10/95
				ZA	9500940 A	09/10/95
				ZA	9500941 A	09/10/95
				RU	2127124 C	10/03/99
				SE	517678 C	02/07/02
				SE	9402456 A	13/01/96
				SE	9500117 D	00/00/00
US	2002040058	A1	04/04/02	EP	1275399 A	15/01/03
				AU	5511401 A	20/11/01
				EP	1282365 A	12/02/03
				WO	0184961 A	15/11/01
WO	0247663	A1	20/06/02	AU	1608502 A	24/06/02
				US	2002114837 A	22/08/02